Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK11 | Q15759 | 12/20 | 1.00 |
| ▸ | MAPK14 | Q16539 | 12/20 | 1.00 |
| ▸ | MAPK13 | O15264 | 11/20 | 1.00 |
| ▸ | MAPK12 | P53778 | 11/20 | 1.00 |
| ▸ | MAPK9 | P45984 | 4/20 | 1.00 |
| ▸ | RAF1 | P04049 | 3/20 | 1.00 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.76 |
| ▸ | CSNK1D | P48730 | 2/20 | 0.76 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.76 |
| ▸ | BRAF | P15056 | 3/20 | 0.59 |
| ▸ | GCGR | P47871 | 7/20 | 0.57 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.57 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.57 |
| ▸ | FRK | P42685 | 1/20 | 0.57 |
| ▸ | GSK3B | P49841 | 1/20 | 0.57 |
| ▸ | PTK6 | Q13882 | 1/20 | 0.57 |
| ▸ | PRKD2 | Q9BZL6 | 1/20 | 0.57 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.57 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4587083 | 1.00 | MAPK11 (1.00) | MAPK11MAPK14MAPK13MAPK12MAPK9 | |
| SCHEMBL1387706 | 0.92 | CSNK1D (0.88) | MAPK11MAPK14MAPK13MAPK12MAPK9 | |
| SCHEMBL19868972 | 0.90 | MAPK14 (0.97) | MAPK11MAPK14MAPK13MAPK12MAPK9 | |
| SCHEMBL19869014 | 0.88 | MAPK14 (1.00) | MAPK11MAPK14MAPK13MAPK12MAPK9 | |
| SCHEMBL19869015 | 0.86 | MAPK13 (0.77) | MAPK11MAPK14MAPK13MAPK12MAPK9 | |
| SCHEMBL4026830 | 0.85 | MAPK14 (1.00) | MAPK11MAPK14MAPK13MAPK12MAPK9 | |
| SCHEMBL9857456 | 0.85 | CSNK1A1 (0.75) | MAPK11MAPK14MAPK13MAPK12MAPK9 | |
| Hydrochloric Acid SCHEMBL4032200 | 0.84 | MAPK14 (0.98) | MAPK11MAPK14MAPK13MAPK12MAPK9 | |
| SCHEMBL14174354 | 0.84 | MAPK13 (0.74) | MAPK11MAPK14MAPK13MAPK12MAPK9 | |
| SCHEMBL4024836 | 0.84 | CSNK1A1 (0.74) | MAPK11MAPK14MAPK13MAPK12MAPK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0854870-B1 | SUBSTITUTED IMIDAZOLES HAVING ANTI-CANCER AND CYTOKINE INHIBITORY ACTIVITY | MERCK & CO INC (US) | 2009-06-10 | — | — | EP | claimed |
| US-20080139596-A1 | Modulators of Hcv Replication | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2008-06-12 | — | — | US | claimed |
| EP-1784189-A1 | MODULATORS OF HCV REPLICATION | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) | 2007-05-16 | — | — | EP | claimed |
| WO-2006021449-A1 | MODULATORS OF HCV REPLICATION | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P ANGELETTI SPA (IT) | 2006-03-02 | — | — | WO | claimed |
| EP-0854870-A4 | SUBSTITUTED IMIDAZOLES HAVING ANTI-CANCER AND CYTOKINE INHIBITORY ACTIVITY | MERCK & CO INC (US) | 1999-01-07 | — | — | EP | claimed |
| EP-0854870-A1 | SUBSTITUTED IMIDAZOLES HAVING ANTI-CANCER AND CYTOKINE INHIBITORY ACTIVITY | Merck & Co., Inc. (US) | 1998-07-29 | — | — | EP | claimed |
| WO-1997012876-A9 | SUBSTITUTED IMIDAZOLES HAVING ANTI-CANCER AND CYTOKINE INHIBITORY ACTIVITY | — | 1997-09-18 | — | — | WO | claimed |
| WO-1997012876-A1 | SUBSTITUTED IMIDAZOLES HAVING ANTI-CANCER AND CYTOKINE INHIBITORY ACTIVITY | MERCK & CO., INC. (US) | 1997-04-10 | — | — | WO | claimed |
| EP-0854870-B1 | SUBSTITUTED IMIDAZOLES HAVING ANTI-CANCER AND CYTOKINE INHIBITORY ACTIVITY | MERCK & CO INC (US) | 2009-06-10 | — | — | EP | disclosed |
| US-20080139596-A1 | Modulators of Hcv Replication | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2008-06-12 | — | — | US | disclosed |
| US-20080139596-A1 | Modulators of Hcv Replication | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2008-06-12 | — | — | US | disclosed |
| US-20080139596-A1 | Modulators of Hcv Replication | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2008-06-12 | — | — | US | disclosed |
| EP-1784189-A1 | MODULATORS OF HCV REPLICATION | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) | 2007-05-16 | — | — | EP | disclosed |
| WO-2006021449-A1 | MODULATORS OF HCV REPLICATION | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P ANGELETTI SPA (IT) | 2006-03-02 | — | — | WO | disclosed |
| CN-1203590-A | Substituted imidazoles having anti-cancer and cytokine inhibitory activity | MERCK & CO INC (US) | 1998-12-30 | — | — | CN | disclosed |
| EP-0854870-A1 | SUBSTITUTED IMIDAZOLES HAVING ANTI-CANCER AND CYTOKINE INHIBITORY ACTIVITY | Merck & Co., Inc. (US) | 1998-07-29 | — | — | EP | disclosed |
| WO-1997045412-A1 | A METHOD OF TREATING CANCER | MERCK & CO., INC. (US) | 1997-12-04 | — | — | WO | disclosed |
| WO-1997036587-A1 | A METHOD OF TREATING CANCER | MERCK & CO., INC. (US) | 1997-10-09 | — | — | WO | disclosed |
| WO-1997012876-A9 | SUBSTITUTED IMIDAZOLES HAVING ANTI-CANCER AND CYTOKINE INHIBITORY ACTIVITY | — | 1997-09-18 | — | — | WO | disclosed |
| WO-1997012876-A1 | SUBSTITUTED IMIDAZOLES HAVING ANTI-CANCER AND CYTOKINE INHIBITORY ACTIVITY | MERCK & CO., INC. (US) | 1997-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139596-A1 | Modulators of Hcv Replication | EIF2AK2, MAVS, IRF3 | MAPK11 3313/4885MAPK14 1644/4885MAPK13 2427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.